[Efficacy of enterocin S760 in treatment of mice with anthrax infection due to Bacillus anthracis M-71]

Antibiot Khimioter. 2011;56(9-10):13-8.
[Article in Russian]

Abstract

The therapeutic efficacy of enterocin S760, a broad spectrum antimicrobial peptide produced by Enterococcus faecium LWP760 was tested on mice infected with Bacillus anthracis M-71 to induce anthrax (second Tsenkovsky's vaccine). Intraperitoneal four-, two- or one-fold administration of the peptide in a dose of 25 mg/kg for 10 days for prophylactic (1 hour after the contamination) and therapeutic (24 hours after the contamination) purposes prevented or cured the infection in 90-100% of the mice versus the 100-percent lethality in the control (untreated animals). The antimicrobial activity of enterocin S760 against B. anthracis M-71 in vivo correlated with activity in vitro. Enterocin S760 is considered a novel promising antimicrobial for the treatment of grampositive and gramnegative infections.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Anthrax / drug therapy*
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / isolation & purification
  • Bacillus anthracis / drug effects*
  • Bacteriocins / administration & dosage*
  • Bacteriocins / isolation & purification
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Enterococcus faecium / chemistry
  • Mice

Substances

  • Anti-Bacterial Agents
  • Bacteriocins
  • bacteriocin S760, Enterococcus faecium